Articles Tagged With: therapeutic
-
Bamlanivimab Injection
Bamlanivimab is a neutralizing recombinant IgG1 monoclonal antibody that connects to the receptor-binding domain of the spike protein of SARS-CoV-2. The drug blocks attachment and entry of the virus into human cells.
-
FDA Issues Third COVID-19 Therapeutic EUA This Month
The list of COVID-19 therapeutics is growing rapidly.
-
FDA Issues Emergency Use Authorization for Bamlanivimab
While the search for a vaccine continues, the agency adds to the list of stop-gap therapeutics to battle COVID-19.
-
Remdesivir Injection (Veklury)
Remdesivir’s benefit appears to be modest, but may be better for those receiving low-flow oxygen.
-
The ABCs of CBD: The Fundamentals of Cannabidiol
Cannabidiol (CBD) is one of two major constituents of marijuana and is the non-psychoactive component of cannabis. As its popularity has grown, questions about CBD from patients to their primary care clinicians have increased dramatically. As a patient advocate interpreting the available evidence, the primary care clinician needs to recognize how CBD differs from marijuana, what its clinical utility might be, and what its risks are.
-
Federal Agencies, Pharma Industry Work to Speed COVID-19 Therapeutics, Vaccine
Public-private partnership aims to streamline, coordinate large-scale efforts.
-
Revamping the Daily Pill: Research to Begin on Monthly Pill
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.
-
Therapeutic Touch for Cancer Pain: An RCT
In a study of 90 men with cancer-related pain, the arm receiving seven sessions of therapeutic touch derived more benefit than a placebo group or a control arm of no intervention.